文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19相关急性呼吸窘迫综合征幸存者的长期心肺功能:多中心病例对照研究

Long-Term Cardiopulmonary Function After COVID-19-Associated Acute Respiratory Distress Syndrome: A Multicenter Case-Control Study.
PubMed 文献 · Crit Care Explor · 2025-07-10
一句话结论COVID-19相关ARDS幸存者出院后约22个月仍存在弥散功能下降、运动能力减低及生活质量受损。

这项多中心病例对照研究纳入114例COVID-19相关ARDS幸存者和115名性别年龄匹配的亲友对照,在幸存者出院至少12个月后(中位22个月)进行肺功能、心肺运动试验、胸部CT和生活质量评估。幸存者常见持续症状(记忆丧失48.2%、乏力42.1%、焦虑31.6%),一氧化碳弥散量(DLCO)及占预计值百分比均显著低于对照,中重度弥散障碍比例更高(10.5% vs 0.8%),峰值耗氧量更低,胸部CT磨玻璃影和肺气肿更常见,生活质量评分更差。提示COVID-19相关ARDS幸存者存在长期多维度心肺功能损害。

要点

  • COVID-19相关ARDS幸存者出院后中位22个月,73.6%仍报告持续症状,记忆丧失48.2%、乏力42.1%、焦虑31.6%。
  • 幸存者DLCO中位6.85 mmol/min/Kpa,低于对照7.36 mmol/min/Kpa(p=0.012),中重度弥散障碍比例10.5% vs 0.8%(p=0.002)。
  • 心肺运动试验峰值耗氧量幸存者21.9 mL/kg/min,低于对照25.8 mL/kg/min(p<0.001)。
  • 胸部CT磨玻璃影幸存者53.5% vs 对照16.5%(p<0.001),肺气肿6.1% vs 0%(p=0.043)。
  • 生活质量EQ-5D-3L效用评分幸存者显著低于对照,活动能力、自我照顾、焦虑/抑郁维度更差。

适用人群与场景

  • COVID-19并发ARDS的幸存者,出院至少12个月后评估;对照为性别年龄匹配的亲友,在纳入时评估。

研究设计与关键结果

  • 多中心病例对照研究,纳入114例COVID-19相关ARDS幸存者和115名性别年龄匹配的亲友对照,平均年龄54岁,52.4%为男性。
  • 幸存者出院至评估时间中位22个月(20.99-41.41个月);73.6%报告持续症状,包括记忆丧失48.2%、乏力42.1%、焦虑31.6%。
  • 幸存者DLCO为6.85 mmol/min/Kpa(5.44-8.37)vs 对照7.36 mmol/min/Kpa(6.43-8.96),p=0.012;DLCO占预计值81.0%(70.2-90.4%)vs 89.3%(78.9-99.9%),p<0.001;中重度DLCO损害10.5% vs 0.8%,p=0.002。
  • 心肺运动试验峰值耗氧量幸存者21.9 mL/kg/min(18.2-29)vs 对照25.8 mL/kg/min(21.6-31.9),p<0.001。
  • 胸部CT磨玻璃影幸存者53.5% vs 对照16.5%,p<0.001;肺气肿6.1% vs 0%,p=0.043。
  • EQ-5D-3L效用评分幸存者显著低于对照,活动能力(p<0.001)、自我照顾(p<0.001)、焦虑/抑郁(p=0.04)维度评分更差。

证据类型、等级与局限

  • 证据类型:多中心病例对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于COVID-19相关ARDS幸存者,出院后中长期随访中需关注弥散功能、运动能力和生活质量的评估。
  • 幸存者持续症状(记忆丧失、乏力、焦虑)常见,提示随访应涵盖这些方面。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to evaluate long-term pulmonary function, cardiopulmonary exercise capacity, chest CT findings, and health-related quality of life (HRQoL) in survivors of COVID-19 complicated by acute respiratory distress syndrome (ARDS).

DESIGN, SETTING, AND PATIENTS: This is a multicentric case-control study conducted from February 2023 to December of 2023. Pulmonary function tests, cardiopulmonary exercise testing (CPET), chest CT, and HRQoL (using EuroQol 5D three-level [EQ-5D-3L]) were performed at least 12 months after hospital discharge among cases (COVID-19 complicated by ARDS) and at the time of inclusion among controls (family members/friends matched for sex and age).

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: A total of 114 COVID-19 ARDS survivors and 115 controls were included. The mean age was 54 years and 52.4% of the participants were men. Time from hospital discharge to evaluation was 22 months (20.99-41.41 mo) among cases. Persistent symptoms, including memory loss (48.2%), fatigue (42.1%), and anxiety (31.6%), were reported by 73.6% of the COVID-19 ARDS survivors. Cases had significantly reduced pulmonary function, with lower diffusing capacity for carbon monoxide (DLCO) of 6.85 mmol/min/Kpa (5.44-8.37 mmol/min/Kpa) vs. 7.36 mmol/min/Kpa (6.43-8.96 mmol/min/Kpa; p = 0.012) and % of predicted DLCO of 81.0% (70.2-90.4%) vs. 89.3% (78.9-99.9%; p < 0.001), compared with controls, as well as a higher frequency of moderate to severe DLCO impairment (10.5% vs. 0.8%; p = 0.002). In CPET, cases demonstrated lower peak oxygen consumption (21.9 mL/kg/min [18.2-29 mL/kg/min] vs. 25.8 mL/kg/min [21.6-31.9 mL/kg/min]; p < 0.001). Chest CT revealed a greater prevalence of ground-glass opacities in cases (53.5% vs. 16.5%; p < 0.001) and emphysema (6.1% vs. 0%; p = 0.043). HRQoL, using EQ-5D-3L utility scores, were significantly lower in cases, with worse mobility (p < 0.001), self-care (p < 0.001), and anxiety/depression (p = 0.04) dimension scores compared with controls.

CONCLUSIONS: COVID-19 ARDS survivors exhibit significant long-term impairments in pulmonary function, exercise capacity, and quality of life and abnormal chest CT findings compared with family controls with same sex and age.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Scolari FL, Rover MM, Trott G, et al. Long-Term Cardiopulmonary Function After COVID-19-Associated Acute Respiratory Distress Syndrome: A Multicenter Case-Control Study. Crit Care Explor. 2025. PMID: 40637450. doi:10.1097/CCE.0000000000001286

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。